Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1

2(33.3%)

N/A

2(33.3%)

Phase 2

1(16.7%)

Phase 3

1(16.7%)

6Total

Phase 1(2)

N/A(2)

Phase 2(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04662879Not ApplicableActive Not Recruiting

Early Detection Initiative for Pancreatic Cancer

Role: lead

NCT05675059Not ApplicableActive Not Recruiting

Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Pancreatic Cancer Patients

Role: collaborator

NCT03192462Phase 1Completed

TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer

Role: collaborator

NCT04581343Phase 1Completed

A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer (PC) Patients

Role: lead

NCT04229004Phase 3Completed

A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer

Role: lead

NCT03848182Phase 2Terminated

Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer

Role: collaborator

All 6 trials loaded